JP2019530649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530649A5 JP2019530649A5 JP2019510580A JP2019510580A JP2019530649A5 JP 2019530649 A5 JP2019530649 A5 JP 2019530649A5 JP 2019510580 A JP2019510580 A JP 2019510580A JP 2019510580 A JP2019510580 A JP 2019510580A JP 2019530649 A5 JP2019530649 A5 JP 2019530649A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- alkyl
- disease
- independently
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 82
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical group 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 8
- 101150065749 Churc1 gene Proteins 0.000 claims description 8
- 102100038239 Protein Churchill Human genes 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000036546 leukodystrophy Diseases 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 201000000585 muscular atrophy Diseases 0.000 claims description 5
- 201000006938 muscular dystrophy Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 4
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 claims description 3
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 claims description 3
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 230000020763 muscle atrophy Effects 0.000 claims description 3
- 208000017445 musculoskeletal system disease Diseases 0.000 claims description 3
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 claims description 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 102000007371 Ataxin-3 Human genes 0.000 claims description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011777 Cystinosis Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010012305 Demyelination Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011252 Phenylketonuria Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 201000009338 distal myopathy Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 210000003000 inclusion body Anatomy 0.000 claims description 2
- 206010023497 kuru Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000023105 myelination Effects 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
- 208000001076 sarcopenia Diseases 0.000 claims description 2
- 210000002955 secretory cell Anatomy 0.000 claims description 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 210000004885 white matter Anatomy 0.000 claims description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 2
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010067601 Dysmyelination Diseases 0.000 claims 1
- 102100034239 Emerin Human genes 0.000 claims 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 claims 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 8
- 0 CCN(CC(CNC)C1NC(NC(C2)(C3)CC23NC(COc2ccc(*)c(F)c2)=O)NCC1)C(F)F Chemical compound CCN(CC(CNC)C1NC(NC(C2)(C3)CC23NC(COc2ccc(*)c(F)c2)=O)NCC1)C(F)F 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- ANEFFUBOBXQWBI-UHFFFAOYSA-N CC(C(C)=C1)NCC1C(NC(C1)(C2)CC12NC(COc(cc1Cl)ccc1Cl)=O)=O Chemical compound CC(C(C)=C1)NCC1C(NC(C1)(C2)CC12NC(COc(cc1Cl)ccc1Cl)=O)=O ANEFFUBOBXQWBI-UHFFFAOYSA-N 0.000 description 1
- ZDUVACLIJUMCFP-UHFFFAOYSA-N CC(C1)NOC1C(NC(CC1)(CCC1(C1)NC(COc(cc2F)ccc2Cl)=O)C1O)=O Chemical compound CC(C1)NOC1C(NC(CC1)(CCC1(C1)NC(COc(cc2F)ccc2Cl)=O)C1O)=O ZDUVACLIJUMCFP-UHFFFAOYSA-N 0.000 description 1
- YAMGDPCPRUPXGA-OAQQODPCSA-N CC(CC(C(NC(CC1)(CCC1(C1)NC(COc(cc2F)ccc2Cl)=O)[C@H]1O)=O)[N+]1(C)[O-])[NH+]1[O-] Chemical compound CC(CC(C(NC(CC1)(CCC1(C1)NC(COc(cc2F)ccc2Cl)=O)[C@H]1O)=O)[N+]1(C)[O-])[NH+]1[O-] YAMGDPCPRUPXGA-OAQQODPCSA-N 0.000 description 1
- DTNIDJKTJITVAE-UHFFFAOYSA-N CC(CC1)OC1C(NC(C1)(C2)CC12NC(COc(cc1)cc(F)c1Cl)=O)=O Chemical compound CC(CC1)OC1C(NC(C1)(C2)CC12NC(COc(cc1)cc(F)c1Cl)=O)=O DTNIDJKTJITVAE-UHFFFAOYSA-N 0.000 description 1
- RRHRDUVGJCQZHQ-UHFFFAOYSA-N CC(N(CC1)CCC1c1ncc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(Cl)c2Cl)=O)=O)[o]1)=O Chemical compound CC(N(CC1)CCC1c1ncc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(Cl)c2Cl)=O)=O)[o]1)=O RRHRDUVGJCQZHQ-UHFFFAOYSA-N 0.000 description 1
- BDXHNNOENAYPGR-UHFFFAOYSA-N CC(N(CC1)CCC1c1ncc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(F)c2Cl)=O)=O)[o]1)=O Chemical compound CC(N(CC1)CCC1c1ncc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(F)c2Cl)=O)=O)[o]1)=O BDXHNNOENAYPGR-UHFFFAOYSA-N 0.000 description 1
- YIQIUENCICNQBC-UHFFFAOYSA-N CC1=NC(C)=CNC1C(NC(CC1)(CCC11NC(COc(cc2)cc(F)c2Cl)=O)CC1O)=O Chemical compound CC1=NC(C)=CNC1C(NC(CC1)(CCC11NC(COc(cc2)cc(F)c2Cl)=O)CC1O)=O YIQIUENCICNQBC-UHFFFAOYSA-N 0.000 description 1
- CAKJKPWITVHKRW-UVBTYCPLSA-N CCC(C1)NOC1C(NC(CC1)(CCC11NC(COc(cc2Cl)ccc2Cl)=O)C[C@@H]1O)=O Chemical compound CCC(C1)NOC1C(NC(CC1)(CCC11NC(COc(cc2Cl)ccc2Cl)=O)C[C@@H]1O)=O CAKJKPWITVHKRW-UVBTYCPLSA-N 0.000 description 1
- MBJQDPYIALWMCJ-UHFFFAOYSA-N CCOc(cc1)ccc1C(NC(C1)(C2)CC12NC(COc(cc1F)ccc1Cl)=O)=O Chemical compound CCOc(cc1)ccc1C(NC(C1)(C2)CC12NC(COc(cc1F)ccc1Cl)=O)=O MBJQDPYIALWMCJ-UHFFFAOYSA-N 0.000 description 1
- BEGBOJGLRPIYSX-UHFFFAOYSA-N CCc(cc1)ccc1C(NC(C1)(C2)CC12NC(COc(cc1F)ccc1Cl)=O)=O Chemical compound CCc(cc1)ccc1C(NC(C1)(C2)CC12NC(COc(cc1F)ccc1Cl)=O)=O BEGBOJGLRPIYSX-UHFFFAOYSA-N 0.000 description 1
- MNBQXWLZTWVTGI-UHFFFAOYSA-N CCc1ccc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(F)c2Cl)=O)=O)nc1 Chemical compound CCc1ccc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(F)c2Cl)=O)=O)nc1 MNBQXWLZTWVTGI-UHFFFAOYSA-N 0.000 description 1
- LZBRTTTZNKQSII-UHFFFAOYSA-N CN(C)CC(CCC1)(CC1C(NC(C1)(C2)CC12NC(COc(cc1)cc(F)c1Cl)=O)=O)C1CCCCCCC1 Chemical compound CN(C)CC(CCC1)(CC1C(NC(C1)(C2)CC12NC(COc(cc1)cc(F)c1Cl)=O)=O)C1CCCCCCC1 LZBRTTTZNKQSII-UHFFFAOYSA-N 0.000 description 1
- LXWPTLQBCFVBDB-UHFFFAOYSA-N COC(C(CCC1)C(NC(C2)(C3)CC23NC(COc(cc2F)ccc2Cl)=O)=O)C1F Chemical compound COC(C(CCC1)C(NC(C2)(C3)CC23NC(COc(cc2F)ccc2Cl)=O)=O)C1F LXWPTLQBCFVBDB-UHFFFAOYSA-N 0.000 description 1
- RSVCDCZMXULRQX-UHFFFAOYSA-N COC(C1)NOC1C(NC(C1)(C2)CC12NC(COc(cc1Cl)ccc1Cl)=O)=O Chemical compound COC(C1)NOC1C(NC(C1)(C2)CC12NC(COc(cc1Cl)ccc1Cl)=O)=O RSVCDCZMXULRQX-UHFFFAOYSA-N 0.000 description 1
- COFRMVDGXCSIDN-UHFFFAOYSA-N COC(C1)NOC1C(NC(C1)(C2)CCC12NC(COc(cc1)cc(F)c1Cl)=O)=O Chemical compound COC(C1)NOC1C(NC(C1)(C2)CCC12NC(COc(cc1)cc(F)c1Cl)=O)=O COFRMVDGXCSIDN-UHFFFAOYSA-N 0.000 description 1
- AVUHTQDJYKFXDL-UHFFFAOYSA-N COC(CC(CC1)C(NC(C2)(C3)CC23NC(COc(cc2F)ccc2Cl)=O)=O)N1C1CCCCCCCCCC1 Chemical compound COC(CC(CC1)C(NC(C2)(C3)CC23NC(COc(cc2F)ccc2Cl)=O)=O)N1C1CCCCCCCCCC1 AVUHTQDJYKFXDL-UHFFFAOYSA-N 0.000 description 1
- HUIRANHGKSZBKU-UHFFFAOYSA-N COCCOc(cc1)cnc1C(NC(C1)(C2)CC12NC(COc(cc1)cc(F)c1Cl)=O)=O Chemical compound COCCOc(cc1)cnc1C(NC(C1)(C2)CC12NC(COc(cc1)cc(F)c1Cl)=O)=O HUIRANHGKSZBKU-UHFFFAOYSA-N 0.000 description 1
- DDAQROMGDYVGDE-UHFFFAOYSA-N COc(cc1)cnc1C(NC(CC1)(CCC11NC(COc(cc2)cc(F)c2Cl)=O)CC1O)=O Chemical compound COc(cc1)cnc1C(NC(CC1)(CCC11NC(COc(cc2)cc(F)c2Cl)=O)CC1O)=O DDAQROMGDYVGDE-UHFFFAOYSA-N 0.000 description 1
- LVAMCAQNMNHNSL-UHFFFAOYSA-N COc1cccc(C(NC(CC2)(CCC22NC(COc(cc3)cc(F)c3Cl)=O)CC2O)=O)n1 Chemical compound COc1cccc(C(NC(CC2)(CCC22NC(COc(cc3)cc(F)c3Cl)=O)CC2O)=O)n1 LVAMCAQNMNHNSL-UHFFFAOYSA-N 0.000 description 1
- KNVFSQFXAMHHPR-UHFFFAOYSA-N COc1ccnc(C(NC(CC2)(CCC22NC(COc(cc3)cc(F)c3Cl)=O)CC2O)=O)c1 Chemical compound COc1ccnc(C(NC(CC2)(CCC22NC(COc(cc3)cc(F)c3Cl)=O)CC2O)=O)c1 KNVFSQFXAMHHPR-UHFFFAOYSA-N 0.000 description 1
- PWTXMWNKOYWUMN-UHFFFAOYSA-N Cc1ccc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(F)c2Cl)=O)=O)nc1 Chemical compound Cc1ccc(C(NC(C2)(C3)CC23NC(COc(cc2)cc(F)c2Cl)=O)=O)nc1 PWTXMWNKOYWUMN-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- YZULNONURCVGQN-UHFFFAOYSA-N O=C(COC(CCC1Cl)CC1F)NC(C1)(C2)CC12NC(C(CCC(C1)Cl)C1NC1)C1C1CCCCCCC1 Chemical compound O=C(COC(CCC1Cl)CC1F)NC(C1)(C2)CC12NC(C(CCC(C1)Cl)C1NC1)C1C1CCCCCCC1 YZULNONURCVGQN-UHFFFAOYSA-N 0.000 description 1
- VAKLUJBOYIMIPI-UHFFFAOYSA-N O=C(COC(CCC1Cl)CC1F)NC(C1)(C2)CC12NC(C1(C2CCCCC2)NCCC1)=O Chemical compound O=C(COC(CCC1Cl)CC1F)NC(C1)(C2)CC12NC(C1(C2CCCCC2)NCCC1)=O VAKLUJBOYIMIPI-UHFFFAOYSA-N 0.000 description 1
- ICXKQYBVPCSPNA-UHFFFAOYSA-N O=C(COC(CCC1Cl)CC1F)NC(C1)(C2)CC12NC(C1CNNCC1)=O Chemical compound O=C(COC(CCC1Cl)CC1F)NC(C1)(C2)CC12NC(C1CNNCC1)=O ICXKQYBVPCSPNA-UHFFFAOYSA-N 0.000 description 1
- IHXHUZPOUIAHLL-UHFFFAOYSA-N O=C(COc(cc1Cl)ccc1Cl)NC(C1)(C2)CC12NC(C1=CN=C2C=CC=CC2N1)=O Chemical compound O=C(COc(cc1Cl)ccc1Cl)NC(C1)(C2)CC12NC(C1=CN=C2C=CC=CC2N1)=O IHXHUZPOUIAHLL-UHFFFAOYSA-N 0.000 description 1
- FAZSULLKSRAUQY-UHFFFAOYSA-N O=C(COc(cc1Cl)ccc1Cl)NC(C1)(C2)CC12NC(c(cn1)ccc1OC(F)(F)F)=O Chemical compound O=C(COc(cc1Cl)ccc1Cl)NC(C1)(C2)CC12NC(c(cn1)ccc1OC(F)(F)F)=O FAZSULLKSRAUQY-UHFFFAOYSA-N 0.000 description 1
- HTQKSQSTJNXDLL-UHFFFAOYSA-N O=C(COc(cc1F)ccc1Cl)NC(C1)(C2)CC12NC(C1OC(C2CC2)NC1)=O Chemical compound O=C(COc(cc1F)ccc1Cl)NC(C1)(C2)CC12NC(C1OC(C2CC2)NC1)=O HTQKSQSTJNXDLL-UHFFFAOYSA-N 0.000 description 1
- GXJVJAJWSHCAHR-UHFFFAOYSA-N O=C(COc(cc1F)ccc1Cl)NC(C1)(C2)CCC12NC(C(CN1)=CC=C1OC(F)(F)F)=O Chemical compound O=C(COc(cc1F)ccc1Cl)NC(C1)(C2)CCC12NC(C(CN1)=CC=C1OC(F)(F)F)=O GXJVJAJWSHCAHR-UHFFFAOYSA-N 0.000 description 1
- BMHBISRKXPSASV-UHFFFAOYSA-N OC(C1)NOC1C(NC(CC1)(CCC11NC(COc(cc2)cc(F)c2Cl)=O)CC1O)=O Chemical compound OC(C1)NOC1C(NC(CC1)(CCC11NC(COc(cc2)cc(F)c2Cl)=O)CC1O)=O BMHBISRKXPSASV-UHFFFAOYSA-N 0.000 description 1
- IVFWABSELTUPIH-UHFFFAOYSA-N OC(CC(CC1)(CC2)NC(C3ONc4c3cccc4)=O)C12NC(COc(cc1)cc(F)c1Cl)=O Chemical compound OC(CC(CC1)(CC2)NC(C3ONc4c3cccc4)=O)C12NC(COc(cc1)cc(F)c1Cl)=O IVFWABSELTUPIH-UHFFFAOYSA-N 0.000 description 1
- XQYAPEPUOZQYFI-UHFFFAOYSA-N OC(CC(CC1)(CC2)NC(COc(cc3F)ccc3F)=O)C12NC(C(NC1)=CCC1C(F)(F)F)=O Chemical compound OC(CC(CC1)(CC2)NC(COc(cc3F)ccc3F)=O)C12NC(C(NC1)=CCC1C(F)(F)F)=O XQYAPEPUOZQYFI-UHFFFAOYSA-N 0.000 description 1
- LMBCBJZXAIEOFP-UHFFFAOYSA-N OC(CC1(CC2CC1)NC(C(C1)ONC1c(c(F)ccc1)c1F)=O)C2NC(COc(cc1)cc(F)c1Cl)=O Chemical compound OC(CC1(CC2CC1)NC(C(C1)ONC1c(c(F)ccc1)c1F)=O)C2NC(COc(cc1)cc(F)c1Cl)=O LMBCBJZXAIEOFP-UHFFFAOYSA-N 0.000 description 1
- ISAPLNHYENHJKT-UHFFFAOYSA-N OC(COc(cc1F)ccc1Cl)NC(C1)(C2)CC12NC(C1NCSC1)=O Chemical compound OC(COc(cc1F)ccc1Cl)NC(C1)(C2)CC12NC(C1NCSC1)=O ISAPLNHYENHJKT-UHFFFAOYSA-N 0.000 description 1
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- WBACTNAITKTUCE-UHFFFAOYSA-N [O-][NH+]1C(NC(C2)(C3)CC23NC(COc(cc2)ccc2Cl)=O)NOC1c(cc1)ccc1Cl Chemical compound [O-][NH+]1C(NC(C2)(C3)CC23NC(COc(cc2)ccc2Cl)=O)NOC1c(cc1)ccc1Cl WBACTNAITKTUCE-UHFFFAOYSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083653A JP2021138718A (ja) | 2016-05-05 | 2021-05-18 | 統合ストレス経路のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332272P | 2016-05-05 | 2016-05-05 | |
| US62/332,272 | 2016-05-05 | ||
| PCT/US2017/031393 WO2017193063A1 (en) | 2016-05-05 | 2017-05-05 | Modulators of the integrated stress pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083653A Division JP2021138718A (ja) | 2016-05-05 | 2021-05-18 | 統合ストレス経路のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530649A JP2019530649A (ja) | 2019-10-24 |
| JP2019530649A5 true JP2019530649A5 (https=) | 2020-06-25 |
| JP6899063B2 JP6899063B2 (ja) | 2021-07-07 |
Family
ID=58709644
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510580A Active JP6899063B2 (ja) | 2016-05-05 | 2017-05-05 | 統合ストレス経路のモジュレーター |
| JP2021083653A Pending JP2021138718A (ja) | 2016-05-05 | 2021-05-18 | 統合ストレス経路のモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021083653A Pending JP2021138718A (ja) | 2016-05-05 | 2021-05-18 | 統合ストレス経路のモジュレーター |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10913727B2 (https=) |
| EP (1) | EP3452456B1 (https=) |
| JP (2) | JP6899063B2 (https=) |
| CN (1) | CN109641854B (https=) |
| AR (1) | AR108395A1 (https=) |
| AU (1) | AU2017261336B2 (https=) |
| CA (1) | CA3023261A1 (https=) |
| MA (1) | MA44863A (https=) |
| TW (1) | TW201808888A (https=) |
| UY (1) | UY37230A (https=) |
| WO (1) | WO2017193063A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN110730777A (zh) * | 2017-06-07 | 2020-01-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4通路抑制剂的化学化合物 |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| US20210145771A1 (en) * | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CN118239937A (zh) * | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| UY37957A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019183589A1 (en) * | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193541A1 (en) * | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| US11478461B2 (en) * | 2018-04-19 | 2022-10-25 | Merck Sharp & Dohme Llc | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors |
| US10689357B2 (en) * | 2018-05-08 | 2020-06-23 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TWI877863B (zh) * | 2018-10-11 | 2025-03-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| MA54953A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| US20200270232A1 (en) * | 2019-02-25 | 2020-08-27 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| CA3137213A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| AR118836A1 (es) * | 2019-04-30 | 2021-11-03 | Calico Life Sciences Llc | Moduladores de la vía de tensión integrada |
| MX2021013197A (es) * | 2019-04-30 | 2022-02-24 | Calico Life Sciences Llc | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| MX2021015210A (es) * | 2019-06-12 | 2022-01-18 | Praxis Biotech LLC | Inhibidores de la via de respuesta al estres integrada. |
| MX2022006087A (es) * | 2019-11-19 | 2022-08-11 | Lupin Ltd | Proceso de preparación de compuestos de cromano. |
| HRP20251132T1 (hr) * | 2020-01-17 | 2025-11-21 | Lupin Limited | Postupci, procesi i međuproizvodi za pripremu spojeva kromana |
| AU2021213289A1 (en) | 2020-01-28 | 2022-07-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2022011143A (es) | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| JP2023546224A (ja) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
| MX2023004623A (es) | 2020-10-22 | 2023-05-12 | Evotec Int Gmbh | Moduladores de la via integrada de respuesta al estres. |
| CN117580824A (zh) * | 2020-10-30 | 2024-02-20 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
| IL302440A (en) * | 2020-10-30 | 2023-06-01 | Calico Life Sciences Llc | Combined pressure pathway modulators |
| WO2023225327A1 (en) * | 2022-05-19 | 2023-11-23 | The Board Of Regents Of The University Of Texas System | Inducers of integrated stress response to treat cancer |
| US20250270202A1 (en) | 2022-06-24 | 2025-08-28 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted 4-aminoisoindoline compound, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| CN121263408A (zh) * | 2023-07-14 | 2026-01-02 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| EP1706384A1 (en) | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Therapeutic agents i |
| CN101142172A (zh) | 2005-01-05 | 2008-03-12 | 艾博特公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
| JP2009504624A (ja) | 2005-08-08 | 2009-02-05 | アージェンタ ディスカバリー リミテッド | ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用 |
| WO2011087758A1 (en) * | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Adamantyl amide derivatives and uses of same |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| JP6806562B2 (ja) * | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| US20160318856A1 (en) | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
-
2017
- 2017-05-04 TW TW106114861A patent/TW201808888A/zh unknown
- 2017-05-05 MA MA044863A patent/MA44863A/fr unknown
- 2017-05-05 UY UY0001037230A patent/UY37230A/es not_active Application Discontinuation
- 2017-05-05 JP JP2019510580A patent/JP6899063B2/ja active Active
- 2017-05-05 WO PCT/US2017/031393 patent/WO2017193063A1/en not_active Ceased
- 2017-05-05 AU AU2017261336A patent/AU2017261336B2/en active Active
- 2017-05-05 EP EP17723904.3A patent/EP3452456B1/en active Active
- 2017-05-05 CA CA3023261A patent/CA3023261A1/en not_active Abandoned
- 2017-05-05 CN CN201780039590.0A patent/CN109641854B/zh active Active
- 2017-05-05 US US16/098,679 patent/US10913727B2/en active Active
- 2017-05-05 AR ARP170101184A patent/AR108395A1/es unknown
-
2020
- 2020-12-01 US US17/108,416 patent/US20220106281A1/en not_active Abandoned
-
2021
- 2021-05-18 JP JP2021083653A patent/JP2021138718A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530649A5 (https=) | ||
| JP2019519599A5 (https=) | ||
| JP2019515043A5 (https=) | ||
| JP2019515042A5 (https=) | ||
| RU2018142740A (ru) | Модуляторы интегрированного сигнального пути стресса | |
| AU2019217320B2 (en) | Steroid derivative regulators, method for preparing the same, and uses thereof | |
| RU2020117900A (ru) | Модуляторы интегрированного стресса | |
| JP2021501786A5 (https=) | ||
| CN114729044B (zh) | 毒蕈碱型乙酰胆碱m1受体拮抗剂 | |
| RU2625789C2 (ru) | N-(пирид-4-ил)амиды и n-(пиримидин-4-ил)амиды и их фармацевтическое и косметическое применение | |
| JP6356888B2 (ja) | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 | |
| IL226912A (en) | The history of triazole, their preparation and their pharmaceutical preparations | |
| JP2013530236A5 (https=) | ||
| WO2007121481A2 (en) | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors | |
| RU2010129929A (ru) | Производные 5-оксо-3-пирролидинкарбоксамида в качестве модуляторов р2х7 | |
| IN2012CH01573A (https=) | ||
| WO2020028724A1 (en) | Substituted-3h-imidazo[4,5-c]pyridine and 1h-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (enpp1) and stimulator for interferon genes (sting) modulators as cancer immunotherapeutics | |
| MX2009009423A (es) | Derivados de 3-ciano-4-(4-fenil-piperidin-1-il)-piridin-2-ona. | |
| JP2009534407A5 (https=) | ||
| AU2019389017B2 (en) | Methods of treating disease with MAGL inhibitors | |
| KR20190077087A (ko) | Magl 억제제 | |
| RU2012142550A (ru) | Производные пирролопиразина и их применение в качестве ингибиторов jak и syk | |
| JPWO2016068287A1 (ja) | 置換ジヒドロピロロピラゾール化合物 | |
| NZ515408A (en) | 5-phenyl-pyrimidine derivatives | |
| JP7736275B2 (ja) | 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 |